ReviewThe AAPS journal2006
Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Have We Neglected to Study Target-Site Drug Exposure in Children? A Systematic Review of the Literature.Clinical pharmacokinetics · 2024Pooled it
- Steady-state plasma pharmacokinetics of oral voriconazole in obese adults.Antimicrobial agents and chemotherapy · 2011Trial
- Skin concentrations and pharmacokinetics of posaconazole after oral administration.Antimicrobial agents and chemotherapy · 2010Trial
- Screening of homing and tissue-penetrating peptides by microdialysis and in vivo phage display.Life science alliance · 2025Article
- Therapeutic Drug Distribution across the Mouse Brain Is Heterogeneous as Revealed by In Vivo, Spatially Resolved Aptamer-Based Sensing.ACS pharmacology & translational science · 2025Article
- A high-precision view of intercompartmental drug transport via simultaneous, seconds-resolved, in situ measurements in the vein and brain.British journal of pharmacology · 2024Article
- Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU.The Journal of antimicrobial chemotherapy · 2024Article
- PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin againstAntibiotics (Basel, Switzerland) · 2022Article
- Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.Clinical pharmacokinetics · 2020Article
- Skin microdialysis: methods, applications and future opportunities-an EAACI position paper.Clinical and translational allergy · 2019Review
- Spatial mapping of drug delivery to brain tissue using hyperspectral spatial frequency-domain imaging.Journal of biomedical optics · 2014Article
- [Tissue penetration of antibiotics. Does the treatment reach the target site?].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.Clinical microbiology reviews · 2013Review
- Pharmacokinetic study on pradofloxacin in the dog - comparison of serum analysis, ultrafiltration and tissue sampling after oral administration.BMC veterinary research · 2013Article
- Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.Drug metabolism and pharmacokinetics · 2009Review
- Development of translational pharmacokinetic-pharmacodynamic models.Clinical pharmacology and therapeutics · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantification of target site pharmacokinetics (PK) is crucial for drug discovery and development. Clinical microdialysis (MD) has increasingly been employed for the description of drug distribution and receptor phase PK of the unbound fraction of various analytes. Costs for MD experiments are comparably low and given suitable analytics, target tissue PK of virtually any drug molecule can be quantified. The major limitation of MD stems from the fact that organs such as brain, lung or liver are not readily accessible without surgery. Recently, non-invasive imaging techniques, i.e. positron emission tomography (PET) or magnetic resonance spectroscopy (MRS), have become available for in vivo drug distribution assessment and allow for drug concentration measurements in practically every human organ. Spatial resolution of MRS imaging, however, is low and although PET enables monitoring of regional drug concentration differences with a spatial resolution of a few millimetres, discrimination between bound and unbound drug or parent compound and metabolite is difficult. Radiotracer development is furthermore time and labour intensive and requires special expertise and radiation exposure and costs originating from running a PET facility cannot be neglected. The recent complementary use of MD and imaging has permitted to exploit individual strengths of these diverse techniques. In conclusion, MD and imaging techniques have provided drug distribution data that have so far not been available. Used alone or in combination, these methods may potentially play an important role in future drug research and development with the potential to serve as translational tools for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.